We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02076269
Recruitment Status : Completed
First Posted : March 3, 2014
Last Update Posted : March 10, 2014
Information provided by (Responsible Party):

Brief Summary:
This purpose of this study is to obtain inhalation profiles in subjects with very severe Chronic Obstructive Pulmonary Disease (COPD). This is a study with no investigational medicinal product. Each subject will attend the clinic on 2 occasions, initially for a screening visit and then for further assessments if included (Visit 1). The maximum time that a subject may be enrolled in the study is 33 days from the screening visit to follow up.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Other: No Intervention Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Characterisation Of Very Severe Chronic Obstructive Pulmonary Disease Patients For Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry
Study Start Date : September 2013
Actual Primary Completion Date : February 2014
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Arm 1
Subjects will receive no treatment in this study. Each subject will attend the clinic on 2 occasions, initially for a screening visit and then for further assessments (Visit 1). Subjects will remain in the study for maximum 33 days from the screening visit to follow up.
Other: No Intervention
Patients are receiving no treatment in this study and there is no investigational product involved

Primary Outcome Measures :
  1. Inhalation profile parameters [ Time Frame: up to approximately 1 month ]
    Following inhalation profile parameters will be obtained using the inhalation profile recorder: Peak Pressure Drop, Peak Inspiratory Flow Rate (PIFR), Inhaled Volume, Inhalation time, Average Inhalation flow, Acceleration rate

  2. Pharyngometry measures [ Time Frame: up to approximately 1 month ]
    Oropharyngeal dimensions will be measured using following parameters of pharyngometry: Distance, Volume, Average cross sectional area.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males/females aged 40 years and over, at the time of signing the informed consent.
  • A female patient is eligible to participate if she is of: Non child-bearing potential, where females are post-menopausal, defined as 12 months of spontaneous amenorrhea [in questionable cases, a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli international units (MIU)/milliliter (mL) and estradiol <40 picograms (pg)/mL (<147 picomoles [pmol]/Liter [L]) is confirmatory] OR Peri-menopausal or pre-menopausal, and have a negative pregnancy test as determined by serum or urine human chorionic gonadotropin (hCG) test, confirmed at screening and at Visit 1, before the computed tomography (CT) scanning is conducted.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
  • Available to complete the study.
  • Clinically diagnosed COPD, for at least 6 months prior to screening: very severe COPD as defined by current GOLD guidelines. The following lung function criteria are post bronchodilator: Very severe COPD. Forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) < 70%, AND FEV1 <30% predicted at screening.
  • Patient is a smoker or an ex smoker with a smoking history of at least 10 pack years (Pack years = (cigarettes per day smoked/20) x number of years smoked)).
  • No history of acute respiratory disease within two weeks prior to inclusion (patients should be back to their usual stable baseline lung function)
  • No history of any other inflammatory lung condition. Patients with previous lung cancer can be included as long as this has been fully treated and they have been free of disease for the preceding 5 years.
  • No exacerbation of disease requiring hospitalisation within the previous two weeks prior to inclusion (patients should be back to their usual stable baseline lung function)
  • Able to withhold from short acting bronchodilators for 6 hours and long acting bronchodilators for 12 hours before the start of the study assessments.

Exclusion Criteria:

  • A patient that has both asthma and COPD.
  • A patient that has a past or present disease, which as judged by the Investigator, may affect patient safety or influence the outcome of the study.
  • History of alcohol abuse.
  • The patient has had a respiratory tract infection within two weeks of the start of the study (patients should be back to their usual stable baseline lung function)
  • The patient has a history of claustrophobia.
  • As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the patient unfit for the study.
  • The patient is unable to perform the Inhalation Profile assessments correctly.
  • The patient has received an investigational drug or device or participated in any other research trial within 30 days of the start of the study.
  • The patient has had any radiological investigations with significant radiation burden (a significant radiation burden defined as International Commission on Radiological Protection (ICRP) category IIb or above: no more than 50 millisievert (mSv) normalised for bodyweight in addition to natural background radiation, in the previous 2 years including the dose from this study).
  • The patient is oxygen (O2) dependant at the time of day when the study assessments are being completed.
  • Unwillingness or inability to follow any of the procedures outlined in the protocol.
  • Patient is kept under regulatory or judicial order in an institution.
  • Patient is mentally or legally incapacitated

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02076269

Layout table for location information
GSK Investigational Site
Edegem, Belgium, 2650
Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02076269    
Other Study ID Numbers: 117178
First Posted: March 3, 2014    Key Record Dates
Last Update Posted: March 10, 2014
Last Verified: March 2014
Keywords provided by GlaxoSmithKline:
Dry Powder Inhaler
Inhalation Profiles
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Aspiration
Respiratory Tract Diseases
Respiration Disorders
Pathologic Processes